Delivery Order SPE2DB24D2010-SPE2DB25FAAAS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with a contract value of $1,672.09 and completion deadline of September 26, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating the award resulted from open competition. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (60 ml) with a ceiling value of $1,575.42. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order is set for ultimate completion by September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency awarded a $1,357.46 delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 150 mL quantity. The contract is structured as a firm fixed price delivery order with a completion date of September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This is a non-set-aside award, indicating the contract was competitively procured through open competition. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $4,169.79. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an Indefinite Delivery Contract (IDC) mechanism. The order is due for completion by April 24, 2025, and will be performed at AmerisourceBergen's headquarters location in Conshohocken,...
- The Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,253.59 and an ultimate completion date of September 19, 2025. The award represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAASDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, valued at $1,742.84. This firm fixed price delivery order, with an ultimate completion date of June 25, 2025, represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with DLA. The award was made through open competition with no set-aside designation, and the product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Quillivant XR, a methylphenidate-based medication used in attention deficit hyperactivity disorder treatment, exemplifies the neurological and specialty pharmaceutical products that AmerisourceBergen routinely delivers to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard, through this flexible contract arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 6/24/25 |